Vmbook Online ordering
Biotechnology
Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development of innovative, life-improving therapies for patients with underserved medical needs. Their primary objective is to leverage their proprietary, selective CB1 receptor agonist, Namodenoson, to treat various conditions, including liver diseases, cancer, and inflammatory disorders. The company strives to make a positive impact on the health industry and enhance the quality of life for individuals worldwide. Their stock symbol on the USA stock exchange is GLMD.
As of March 20, 2023, Galmed Pharmaceuticals' stock price was $1.92, exhibiting a 52-week range of $1.29 - $6.80. The company has a market capitalization of $32.91 million, 17.78 million outstanding shares, and a P/E ratio of -1.92. The stock's moving average over 50 days and 200 days is $1.55 and $1.83, respectively. The company's earnings per share (EPS) are -0.56, and its beta is 1.69. The company has 77.04 million shares in its float, 24.67 million more shares than its 3-month average volume of 52.38 million.
Galmed Pharmaceuticals' last earnings report was released on November 29, 2022. The report revealed a negative EPS of $0.18 in the third quarter of 2022, surpassing the consensus estimate of -$0.22. With a negative earnings surprises of 18.2%, actual EPS was higher than the anticipated value. The company's revenues for the quarter were $0.98 million, While the company's revenue for the quarter was $0.98 million, surpassing the consensus estimates by 11.11%. Over the past year, Galmed Pharmaceuticals' stock has encountered a decline of approximately -30.77%. During the past 65 days, the stock has experienced a decrease of -20.00%.
Analysts' forecasts for Galmed Pharmaceuticals have been revised upward over the past 90 days, with their EPS estimates rising by 26.33%. The company's stock has generated significant interest from retail investors, with a 35.15% increase in ownership over the past 90 days. Institutional ownership of Galmed Pharmaceuticals stands at 13.90%, with the company's insiders holding 19.80% of the total shares.
Overall, Galmed Pharmaceuticals is a promising clinical-stage biotechnology company committed to developing innovative therapies for various medical needs. Although its stock performance has been affected by industry and market trends, the company's pipeline and clinical trial progress hold promise for its future success.
Here are some key points about Galmed Pharmaceuticals:
1. Galmed Pharmaceuticals focuses on developing innovative therapies for underserved medical needs, with a pipeline including Namodenoson for liver diseases, cancer, and inflammatory disorders.
2. GLMD's stock price, on March 20, 2023, was $1.92, with a market capitalization of $32.91 million, 17.78 million outstanding shares, and a P/E ratio of -1.92.
3. The stock's 52-week range is $1.29 - $6.80, and its moving averages for 50 and 200 days are $1.55 and $1.83, respectively.
4. The company's EPS is -0.56, and its beta is 1.69.
5. Galmed Pharmaceuticals' last earnings report was released on November 29, 2022. The negative EPS of $0.18 surpassed the consensus estimate of -0.22, with a negative earnings surprise of 18.2%.
6. Revenues for the quarter were $0.98 million, surpassing consensus estimates by 11.11%.
7. Galmed Pharmaceuticals' stock has seen a decline of -30.77% over the past year but has recently experienced a -20.00% decrease within the past 65 days.
8. Analysts have revised their earnings estimates for Galmed Pharmaceuticals upward by 26.33% over the past 90 days.
9. Retail investors have shown significant interest in the company's stock, leading to a 35.15% increase in ownership over the past 90 days.
10. Institutional ownership stands at 13.90%, with insiders holding 19.80% of the total shares.
11. Despite these challenges, Galmed Pharmaceuticals holds promise for future success with its pipeline and clinical trial progress.
Overall, while Galmed Pharmaceuticals faces industry and market challenges, its commitment to developing life-improving therapies holds promise for its future success.
I hope this article helps you.